196 related articles for article (PubMed ID: 34059075)
1. Brain HIV-1 latently-infected reservoirs targeted by the suicide gene strategy.
Saeb S; Ravanshad M; Pourkarim MR; Daouad F; Baesi K; Rohr O; Wallet C; Schwartz C
Virol J; 2021 May; 18(1):107. PubMed ID: 34059075
[TBL] [Abstract][Full Text] [Related]
2. Microglial Cells: The Main HIV-1 Reservoir in the Brain.
Wallet C; De Rovere M; Van Assche J; Daouad F; De Wit S; Gautier V; Mallon PWG; Marcello A; Van Lint C; Rohr O; Schwartz C
Front Cell Infect Microbiol; 2019; 9():362. PubMed ID: 31709195
[TBL] [Abstract][Full Text] [Related]
3. Brain macrophages harbor latent, infectious simian immunodeficiency virus.
Abreu C; Shirk EN; Queen SE; Beck SE; Mangus LM; Pate KAM; Mankowski JL; Gama L; Clements JE
AIDS; 2019 Dec; 33 Suppl 2(Suppl 2):S181-S188. PubMed ID: 31789817
[TBL] [Abstract][Full Text] [Related]
4. TLR1/2 Agonist Enhances Reversal of HIV-1 Latency and Promotes NK Cell-Induced Suppression of HIV-1-Infected Autologous CD4
Duan S; Xu X; Wang J; Huang L; Peng J; Yu T; Zhou Y; Cheng K; Liu S
J Virol; 2021 Aug; 95(17):e0081621. PubMed ID: 34133900
[TBL] [Abstract][Full Text] [Related]
5. A flexible model of HIV-1 latency permitting evaluation of many primary CD4 T-cell reservoirs.
Lassen KG; Hebbeler AM; Bhattacharyya D; Lobritz MA; Greene WC
PLoS One; 2012; 7(1):e30176. PubMed ID: 22291913
[TBL] [Abstract][Full Text] [Related]
6. Posttranscriptional Regulation of HIV-1 Gene Expression during Replication and Reactivation from Latency by Nuclear Matrix Protein MATR3.
Sarracino A; Gharu L; Kula A; Pasternak AO; Avettand-Fenoel V; Rouzioux C; Bardina M; De Wit S; Benkirane M; Berkhout B; Van Lint C; Marcello A
mBio; 2018 Nov; 9(6):. PubMed ID: 30425153
[TBL] [Abstract][Full Text] [Related]
7. The Effect of JAK1/2 Inhibitors on HIV Reservoir Using Primary Lymphoid Cell Model of HIV Latency.
de Armas LR; Gavegnano C; Pallikkuth S; Rinaldi S; Pan L; Battivelli E; Verdin E; Younis RT; Pahwa R; Williams SL; Schinazi RF; Pahwa S
Front Immunol; 2021; 12():720697. PubMed ID: 34531866
[TBL] [Abstract][Full Text] [Related]
8. Current Strategies for Elimination of HIV-1 Latent Reservoirs Using Chemical Compounds Targeting Host and Viral Factors.
Jean MJ; Fiches G; Hayashi T; Zhu J
AIDS Res Hum Retroviruses; 2019 Jan; 35(1):1-24. PubMed ID: 30351168
[TBL] [Abstract][Full Text] [Related]
9. Deep latency: A new insight into a functional HIV cure.
Elsheikh MM; Tang Y; Li D; Jiang G
EBioMedicine; 2019 Jul; 45():624-629. PubMed ID: 31227439
[TBL] [Abstract][Full Text] [Related]
10. Astrocytes sustain long-term productive HIV-1 infection without establishment of reactivable viral latency.
Barat C; Proust A; Deshiere A; Leboeuf M; Drouin J; Tremblay MJ
Glia; 2018 Jul; 66(7):1363-1381. PubMed ID: 29464785
[TBL] [Abstract][Full Text] [Related]
11. Reactivation Kinetics of HIV-1 and Susceptibility of Reactivated Latently Infected CD4+ T Cells to HIV-1-Specific CD8+ T Cells.
Walker-Sperling VE; Cohen VJ; Tarwater PM; Blankson JN
J Virol; 2015 Sep; 89(18):9631-8. PubMed ID: 26178987
[TBL] [Abstract][Full Text] [Related]
12. HIV Eradication Strategies: Implications for the Central Nervous System.
Veenhuis RT; Clements JE; Gama L
Curr HIV/AIDS Rep; 2019 Feb; 16(1):96-104. PubMed ID: 30734905
[TBL] [Abstract][Full Text] [Related]
13. The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency.
Mousseau G; Kessing CF; Fromentin R; Trautmann L; Chomont N; Valente ST
mBio; 2015 Jul; 6(4):e00465. PubMed ID: 26152583
[TBL] [Abstract][Full Text] [Related]
14. A Review of Current Strategies Towards the Elimination of Latent HIV-1 and Subsequent HIV-1 Cure.
Maina EK; Adan AA; Mureithi H; Muriuki J; Lwembe RM
Curr HIV Res; 2021; 19(1):14-26. PubMed ID: 32819259
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 Latency and Viral Reservoirs: Existing Reversal Approaches and Potential Technologies, Targets, and Pathways Involved in HIV Latency Studies.
Khanal S; Schank M; El Gazzar M; Moorman JP; Yao ZQ
Cells; 2021 Feb; 10(2):. PubMed ID: 33672138
[TBL] [Abstract][Full Text] [Related]
16. Finding a cure for HIV: will it ever be achievable?
Lewin SR; Evans VA; Elliott JH; Spire B; Chomont N
J Int AIDS Soc; 2011 Jan; 14():4. PubMed ID: 21255462
[TBL] [Abstract][Full Text] [Related]
17. The Pathway To Establishing HIV Latency Is Critical to How Latency Is Maintained and Reversed.
Rezaei SD; Lu HK; Chang JJ; Rhodes A; Lewin SR; Cameron PU
J Virol; 2018 Jul; 92(13):. PubMed ID: 29643247
[TBL] [Abstract][Full Text] [Related]
18. Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4
Madrid-Elena N; García-Bermejo ML; Serrano-Villar S; Díaz-de Santiago A; Sastre B; Gutiérrez C; Dronda F; Coronel Díaz M; Domínguez E; López-Huertas MR; Hernández-Novoa B; Moreno S
J Virol; 2018 May; 92(9):. PubMed ID: 29444937
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 Latency and Eradication: Past, Present and Future.
Datta PK; Kaminski R; Hu W; Pirrone V; Sullivan NT; Nonnemacher MR; Dampier W; Wigdahl B; Khalili K
Curr HIV Res; 2016; 14(5):431-441. PubMed ID: 27009094
[TBL] [Abstract][Full Text] [Related]
20. Modeling HIV-1 Latency Using Primary CD4
Takata H; Kessing C; Sy A; Lima N; Sciumbata J; Mori L; Jones RB; Chomont N; Michael NL; Valente S; Trautmann L
J Virol; 2019 Jun; 93(11):. PubMed ID: 30918072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
